Literature DB >> 11478855

Phosphorylation of raf-1 by kinase suppressor of ras is inhibited by "MEK-specific" inhibitors PD 098059 and U0126 in differentiating HL60 cells.

X Wang1, G P Studzinski.   

Abstract

Determination of the involvement of MAP kinase cascades in signaling cell growth or differentiation is aided by the use of the inhibitors PD 098059 [2-(2'-amino-3'-methoxyphenyl)oxananphthalen-4-one] and U0126 [1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene], believed to be MEK-specific kinase inhibitors. We report here that the activity of kinase suppressor of ras (KSR-1), a kinase upstream of raf-1, is inhibited by both these compounds at concentrations similar to those that inhibit MEK-1. Further, in HL60 cells induced to differentiate with 1,25-dihydroxyvitamin D(3) raf-1 and p90RSK, but not ERK1/2, are coregulated, and their expression as well as monocytic differentiation is inhibited in parallel by PD 098059. Thus, in this system raf-1 is phosphorylated by KSR-1, and PD 098059 as well as U0126 inhibits this phosphorylation. This suggests great caution in the interpretation of experiments that utilize these pharmacological inhibitors of kinase activity as evidence for a role for the MEK--ERK module in ras or raf-1 signaling. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11478855     DOI: 10.1006/excr.2001.5292

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  11 in total

Review 1.  Vitamin D and differentiation in cancer.

Authors:  Elzbieta Gocek; George P Studzinski
Journal:  Crit Rev Clin Lab Sci       Date:  2009       Impact factor: 6.250

2.  Role of reactive oxygen species in extracellular signal-regulated protein kinase phosphorylation and 6-hydroxydopamine cytotoxicity.

Authors:  Scott M Kulich; Charleen T Chu
Journal:  J Biosci       Date:  2003-02       Impact factor: 1.826

3.  The rationale for deltanoids in therapy for myeloid leukemia: role of KSR-MAPK-C/EBP pathway.

Authors:  George P Studzinski; Xuening Wang; Yan Ji; Qing Wang; Yingyu Zhang; Andrzej Kutner; Jonathan S Harrison
Journal:  J Steroid Biochem Mol Biol       Date:  2005-07-25       Impact factor: 4.292

4.  Raf-1 signaling is required for the later stages of 1,25-dihydroxyvitamin D3-induced differentiation of HL60 cells but is not mediated by the MEK/ERK module.

Authors:  Xuening Wang; George P Studzinski
Journal:  J Cell Physiol       Date:  2006-11       Impact factor: 6.384

Review 5.  Inflammatory bowel disease reveals the kinase activity of KSR1.

Authors:  Richard Kolesnick; H Rosie Xing
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

6.  Role of the serine-threonine kinase PAK-1 in myxoma virus replication.

Authors:  J B Johnston; John W Barrett; Wen Chang; Che-Sheng Chung; Wei Zeng; Jennefer Masters; Melissa Mann; Fuan Wang; Jingxin Cao; Grant McFadden
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

7.  Kinase suppressor of Ras transphosphorylates c-Raf-1.

Authors:  Mohammad Zafrullah; Xianglei Yin; Adriana Haimovitz-Friedman; Zvi Fuks; Richard Kolesnick
Journal:  Biochem Biophys Res Commun       Date:  2009-09-17       Impact factor: 3.575

8.  Induction of differentiation of human leukemia cells by combinations of COX inhibitors and 1,25-dihydroxyvitamin D3 involves Raf1 but not Erk 1/2 signaling.

Authors:  Farnaz Jamshidi; Jing Zhang; Jonathan S Harrison; Xuening Wang; George P Studzinski
Journal:  Cell Cycle       Date:  2008-01-14       Impact factor: 4.534

Review 9.  Vitamin D3-driven signals for myeloid cell differentiation--implications for differentiation therapy.

Authors:  Philip J Hughes; Ewa Marcinkowska; Elzbieta Gocek; George P Studzinski; Geoffrey Brown
Journal:  Leuk Res       Date:  2009-10-06       Impact factor: 3.156

10.  Downregulation of protein kinase CK2 induces autophagic cell death through modulation of the mTOR and MAPK signaling pathways in human glioblastoma cells.

Authors:  Birgitte B Olsen; Tina H Svenstrup; Barbara Guerra
Journal:  Int J Oncol       Date:  2012-09-21       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.